Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-21
2005-06-21
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S456000
Reexamination Certificate
active
06908943
ABSTRACT:
The present invention is generally related to the discovery of the therapeutic benefit of administering γ-tocopherol and γ-tocopherol derivatives. More specifically, the use of γ-tocopherol and racemic LLU-α, (S)-LLU-α, or γ-tocopherol derivatives as antioxidants and nitrogen oxide scavengers which treat and prevent high blood pressure, thromboembolic disease, cardiovascular disease, cancer, natriuretic disease, the formation of neuropathological lesions, and a reduced immune system response are disclosed.
REFERENCES:
patent: 4144325 (1979-03-01), Voyt
patent: 4321270 (1982-03-01), Sundeen
patent: 4914197 (1990-04-01), Yamamoto et al.
patent: 5106630 (1992-04-01), Bricker et al.
patent: 5139796 (1992-08-01), Barkalow et al.
patent: 5200214 (1993-04-01), Barkalow et al.
patent: 5270060 (1993-12-01), Foster et al.
patent: 5422393 (1995-06-01), Bricker et al.
patent: 5739156 (1998-04-01), Bissett
patent: 6048891 (2000-04-01), Wechter
patent: 6083982 (2000-07-01), Wechter et al.
patent: 6150402 (2000-11-01), Wechter et al.
patent: 6242479 (2001-06-01), Wechter
patent: 6410589 (2002-06-01), Wechter
patent: 6417223 (2002-07-01), Sanders et al.
patent: 6426362 (2002-07-01), Miller et al.
patent: 6555575 (2003-04-01), Wechter
patent: 6703384 (2004-03-01), Sanders et al.
patent: 2002/0040053 (2002-04-01), Kondo et al.
patent: 2002/0107207 (2002-08-01), Sanders et al.
patent: 2002/0132845 (2002-09-01), Miller et al.
patent: 2002/0143049 (2002-10-01), Miller et al.
patent: 2002/0156024 (2002-10-01), Sanders et al.
patent: 2003/0013656 (2003-01-01), Wang et al.
patent: 2003/0013657 (2003-01-01), Wang et al.
patent: 2003/0013846 (2003-01-01), Wang et al.
patent: 2003/0013847 (2003-01-01), Wang et al.
patent: 2003/0022818 (2003-01-01), Wang et al.
patent: 2004/0097431 (2004-05-01), Sanders et al.
patent: 0 326 987 (1989-08-01), None
patent: 0 350 913 (1990-01-01), None
patent: 0 413 668 (1991-02-01), None
patent: WO 96/05191 (1996-02-01), None
patent: WO 96/19215 (1996-06-01), None
Isselbacher, et al., Ed's, Harrison's Principles of Internal Medicine, 13thed., vol. 2, McGraw-Hill, New York, 1994.
Beharka, et al., “Vitamin E Status and Immune Function,” Methods in Enzymology, vol. 282, pp. 247-263, 1997.
Benaksas, et al., Life Sciences, 52:1045-54 (1993).
Bottje et al., “Effect of Dietary d1-alpha-Tocopherol on tissue alpha- and Gamma-Tocopherol and Pulmonary Hypertension Syndrome (Ascities in Broilers,” Poultry Science, 76:1506-12, Abstract Only (1997).
Burnett, et al., “Mechanisms of Phytochemical Inhibition . . . ,” American Chemical Society Symposium Series, pp. 45-58, 1998.
Campo, et al.,Free Radical Biology and Medicine, “Reduction of Myocardial Infarct Size in rat by IRFI-048, a selective analogue of Vitamin E”, vol. 16, pp. 427-435 (1994).
Campo, et al.,Pharmacology, “Protective Effects of IRF-016, a New Antioxidant Agent, in Myocardial Damage, following coronary artery occlusion and reperfusion in the rat”, 48:157-166 (1994).
Campo, et al.,Research Comm. in Chem. Pathology and Pharmacology, “IRFI-016, a new radical scavenger, limits ischemic damage following coronary artery occlusion in rats”, vol. 76, No., pp. 287-303, (1992).
Christen et al., “γ-Tocopheral Traps Mutagenic Electrophiles such as NOxand Complements alpha-Tocopheral: Physiological Implications,” Proc. Natl. Acad. Sci., USA, 94(7):3217-22 (1997).
Elson, Charles E., “Impact of Palm Oil on Experimental Carcinogenesis,” Vitamine E in Health and Disease, Packer & Fuchs eds, Chapter 39, pp. 533-545 (1993).
Frei & Ames, “Relative Importance of Vitamine E in Antiperoxidative Defenses in Human Blood Plasma and Low-Density Lipoprotein (LDL),” Vitamine E in Health and Disease, Packer & Fucks eds, Chapter 10, pp. 131-139 (1993).
Germano, Carl, http://www.solgar.com
utrition_library/articles/tocotrienols.html, Posted Nov. 27, 1997, 4 pgs., “Tocotrienols in Health & Disease: A Novel Antioxidant in the Treatment of Hypercholesterolemia and Cancer.”.
Kantoci et al., “Endogenous Natriuretic Factors 6: The Stereochemistry of a Natriuretic γ-Tocopherol Metabolite LLU-α,” Journal of Pharmacology and Experimental Therapeutics, 282(2):648-656 (1997).
Life Extension Foundation, http://lef.org/prod_desc/item564.html, (1995-1999), 2 pgs., “Gamma E Tocopherol Formula.”.
Life Extension Foundation, http://lef.org/cgi-local/shop.pl/page=feb98_newproduct.html, (1995-1999), 3 pgs., “Not all Vitamin E is Created Equal.”.
McLaughlin & Weihrauch, “Vitamin E Content of Foods,” Journal of the American Dietetic Association, 75:6547-665 (1979).
Meydani, Mohsen, “Vitamin E,” The Lancet, 345:170-175 (1995).
Meydani, S. & R. Tengerdy, “Vitamin E and Immune Response,” Vitamine E in Health and Disease, Packer & Fuchs eds, Chapter 40, pp. 549-561 (1993).
Murray, David E. et al., “Endogenous Natriuretic Factors 7: Biospecificity of a Natriuretic γ-Tocopherol Metabolite LLU-α1,” The Journal of Pharmacology and Experimental Therapeutics, vol. 282, pp. 657-662 (1992).
Nando.net & The Associated Press, http://www.nando.net
ewsroom
tn/health/033197/health12-4931.html, 1997, 2 pgs., “Too Much Vitamin E Can be Harmful.”.
Odeleve, et al., “The Potential Role of Vitamin E in the Treatment of Immunologic Abnormalities During Acquired Immune Deficiency Syndrome,” Database Medline, 1991.
Packer et al., “Significance of Vitamin E for the Athlete,” Vitamine E in Health and Disease, Packer & Fuchs eds, (1993) Chapter 34, pp. 465-471.
Richardson et al., “Adhesion of Human Platelets Inhibited by Vitamin E,” Vitamine E in Health and Disease, Packer & Fuchs eds, 1993, Ch. 24, pp. 297-311.
Shigenaga et al., “Inflammation and NOx-induced Nitration: Assay for 3-nitrotyrosine by HPLC with Electrochemical Detection,” Proc. Natl. Acad. Sci. USA, 94(7):3211-3216 (1997).
Speek et al., “Vitamin E Composition of Some Speed Oils as Determined by High-Performance Liquid Chromatography with Fluorometric Detection,” Journal of Food Science, 501:121-124 (1985).
Stone, et al., “Tocopherols and the Etiology of Colon Cancer,” Journal of the National Cancer Institute, vol. 89, pp. 1006-1014, 1997.
The Merck Index, 11thedition, published by Merck & Co., Inc. (NJ), 1989, citation 9418, p. 1495.
Wechter et al., “A New Endogenous Natriuretic Factor: LLU-α,” Proc. Natl. Acad. Sci. USA, 93:6002-6007 (1996).
Weichert et al., “Studien in der Gruppe der Vitamine K und E vi. Über die Darstellung von 2, 5, 7, 8, -Tetramethyl-2-(β-Carboxy-Äthyl)-6-Hydroxychroman und Dessen Oxydationsprodukt,” Collection Czechoslov. Chem. Commun., 24:1689-1694 (1959) No Translation.
Official Monographs, “Vitamin E,” “Vitamin E Preparation,” and “Vitamin E Capsules,” USP 23, pp. 1631-1633 no date provided.
“Myraid Genetics Plans to Launch the First Genetic Test for High Blood Pressure,” Genetic Engineering News, p. 27 (1997).
Yarita, et al., “Supercritical Fluid Chromatographic Determination of Cholesterol and Cholesteryl Esters in Serum on ODS-Silica Gel Column,” Journal of Chromatography A., vol. 679, pp. 329-334, 1994.
Henley III Raymond J.
Knobbe Martens Olson & Bear LLP
Loma Linda University Medical Center
LandOfFree
Use of γ-tocopherol and its oxidative metabolite... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of γ-tocopherol and its oxidative metabolite..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of γ-tocopherol and its oxidative metabolite... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3467282